Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2026-02-05 @ 11:44 PM
Study NCT ID:
NCT00675259
Status:
COMPLETED
Last Update Posted:
2018-07-24
First Post:
2008-05-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
OSU-07074
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None